预约演示
更新于：2024-12-31
Paroxetine Hydrochloride
盐酸帕罗西汀
更新于：2024-12-31
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H21ClFNO3 |
InChIKeyGELRVIPPMNMYGS-RVXRQPKJSA-N |
CAS号78246-49-8 |
关联
211
项与 盐酸帕罗西汀 相关的临床试验JPRN-UMIN000054623
The effect of different doses of paroxetine in premature ejaculation: a prospective randomized cross-over clinical trial - The effect of different doses of paroxetine in premature ejaculation: a prospective randomized cross-over clinical trial
NCT06232109
Phase 1, Open-Label, Parallel Group Drug-Drug Interaction Study to Assess the Effect of Fluvoxamine (CYP2C19 Inhibitor), Itraconazole (CYP3A4 Inhibitor) and Paroxetine (CYP2D6 Inhibitor) on the Pharmacokinetics of ASN51 in Healthy Subjects
CTR20234012
盐酸帕罗西汀片在中国健康受试者中进行的单中心、随机、开放、单剂量、两周期交叉空腹及餐后状态下的人体生物等效性试验
100 项与 盐酸帕罗西汀 相关的临床结果
登录后查看更多信息
100 项与 盐酸帕罗西汀 相关的转化医学
登录后查看更多信息
100 项与 盐酸帕罗西汀 相关的专利（医药）
登录后查看更多信息
3,478
项与 盐酸帕罗西汀 相关的文献（医药）2025-01-01PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
Comparative safety of prescribed Esketamine and ketamine in relation to renal and urinary disorders: A pharmacovigilance perspective
Article
作者: Floresta, G ; Chiappini, S ; Martinotti, G ; Corkery, J M ; Duccio Papanti, G ; Mosca, A ; Arillotta, D ; Schifano, F ; Semeraro, F ; D'Andrea, G ; Schifano, N ; Guirguis, A
Intranasal esketamine, approved with oral antidepressants for adults with treatment-resistant depression (TRD), is the S-enantiomer of ketamine and has higher potency and affinity for N-Methyl-d-Aspartate receptors. Administered intranasally, it offers rapid absorption and onset, essential for severe depressive symptoms or suicidal impulses. Comparative studies on esketamine and ketamine's urological safety profiles show esketamine has lower or comparable risks of renal and urinary disorders. Ketamine, however, has documented cases of nephrotoxicity and severe urological issues in recreational users. The study aims to further evaluate and compare these profiles against other antidepressants and antipsychotics using the Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS) data. ADR cases were reported to the FDA up to May 12, 2024, being drugs listed including esketamine, ketamine, quetiapine, aripiprazole, olanzapine, risperidone, citalopram, escitalopram, paroxetine, fluoxetine, sertraline, duloxetine, venlafaxine, amitriptyline, and clomipramine. Risperidone showed the highest ADRs (107,418) and serious cases (71,515), with significant renal and urinary disorders reported, including acute kidney injury and urinary incontinence. Olanzapine, quetiapine, and aripiprazole also had high serious ADRs. Venlafaxine and fluoxetine were notable among antidepressants for acute kidney injury. Esketamine and ketamine were associated with lower urinary tract symptoms and nephrolithiasis. Disproportionality analysis revealed ketamine had higher odds of renal and urinary disorders compared to other drug classes, while esketamine had lower or comparable odds. The data suggest a relatively favorable tolerability profile for these drugs, especially esketamine. However, the results highlight the necessity for more extensive studies to evaluate long-term safety and optimize treatment protocols.
2024-12-01JOURNAL OF NEUROSCIENCE RESEARCH
Anxiety‐Like Behaviors in Mice Unmasked: Revealing Sex Differences in Anxiety Using a Novel Light‐Heat Conflict Test
Article
作者: Park, Sung‐Hoon ; Gaudet, Andrew D. ; Fonken, Laura K. ; Aldrich, John C. ; Lee, Sydney E.
ABSTRACT:
Anxiety and chronic pain afflict hundreds of millions worldwide. Anxiety and pain are more prevalent in females compared to males. Unfortunately, robust sex differences in human anxiety are not recapitulated in rodent tests, and results from rodent pain studies frequently fail to translate clinically. Therefore, there is a need to develop tests that reflect the differential salience of anxiety or pain‐related stimuli between the sexes. Accordingly, here we introduce the Thermal Increments Dark–Light (TIDAL) conflict test. The TIDAL test places an anxiety‐relevant stimulus (dark vs. illuminated chamber) in conflict with a heat‐related stimulus (incrementally heated vs. isothermic chamber); mice freely explore both apparatus chambers. Here, we aim to determine whether the TIDAL conflict test reveals in mice underappreciated sex differences in anxiety and/or heat sensitivity. We establish in four distinct experiments that females on the TIDAL conflict test persist substantially longer on the dark‐heated plate, suggesting that female mice exhibit elevated anxiety‐like behavior. Mice more strongly prefer the heated‐dark plate on the TIDAL conflict test compared to control thermal place preference with both chambers illuminated. We also reveal that an anxiety‐relieving drug, paroxetine, reduces mouse preference for the heating dark plate, supporting the validity of the TIDAL test. Therefore, our new TIDAL conflict test reliably unmasks the relative salience of anxiety (vs. heat sensitivity): mice that are female exhibit robust anxiety‐like behaviors not consistently observed in classical tests. Future studies should incorporate TIDAL and other conflict tests to better understand rodent behavior and to identify mechanisms underlying anxiety and pain.
2024-11-23Translational Neuroscience
Identifying key biomarkers and therapeutic candidates for post-COVID-19 depression through integrated omics and bioinformatics approaches
Article
作者: Zhou, Jing ; Yang, Chunhua ; Sui, Xingling ; Dong, Hongyu ; Zhou, Yi ; Zhang, Qiyao ; Zhang, Haidong ; Wang, Yue
Abstract:
Introduction:
Depression, the leading cause of disability worldwide, is known to be exacerbated by severe acute respiratory syndrome coronavirus 2 infection, worsening coronavirus disease 2019 (COVID-19) outcomes. However, the mechanisms and treatments for this comorbidity are not well understood.
Methods:
This study utilized Gene Expression Omnibus datasets for COVID-19 and depression, combined with protein–protein interaction networks, to identify key genes. Gene ontology and Kyoto Encyclopedia of Genes and Genomes analyses were performed to understand gene functions. The CIBERSORT algorithm and NetworkAnalyst were used to examine the relationship of immune cell infiltration with gene expression and to predict transcription factors (TFs) and microRNAs (miRNAs) interactions. The Connectivity Map database was used to predict drug interactions with these genes.
Results:
TRUB1, PLEKHA7, and FABP6 were identified as key genes enriched in pathways related to immune cell function and signaling. Seven TFs and nineteen miRNAs were found to interact with these genes. Nineteen drugs, including atorvastatin and paroxetine, were predicted to be significantly associated with these genes and potential therapeutic agents for COVID-19 and depression.
Conclusions:
This research provides new insights into the molecular mechanisms of post-COVID-19 depression and suggests potential therapeutic strategies, marking a step forward in understanding and treating this complex comorbidity.
100 项与 盐酸帕罗西汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 经前焦虑症 | 美国 | 2003-08-28 | |
| 恐慌 | 日本 | 2000-09-22 | |
| 广泛性焦虑障碍 | 美国 | 1997-06-25 | |
| 创伤后应激障碍 | 美国 | 1997-06-25 | |
| 抑郁症 | 中国 | 1995-01-01 | |
| 重度抑郁症 | 美国 | 1992-12-29 | |
| 强迫症 | 美国 | 1992-12-29 | |
| 惊恐障碍 | 美国 | 1992-12-29 | |
| 社交恐怖症 | 美国 | 1992-12-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 中度重度抑郁症 | 临床2期 | 保加利亚 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 加拿大 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 智利 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 哥斯达黎加 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 克罗地亚 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 法国 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 德国 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 印度 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 意大利 | 2006-12-19 | |
| 中度重度抑郁症 | 临床2期 | 波兰 | 2006-12-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 38 | (Participants Who Received Paroxetine 20 mg) | 壓構醖膚廠齋範糧淵鹹(齋醖觸窪壓簾簾廠製繭) = 夢築鹹艱積鹹憲齋壓獵 願蓋膚鑰遞廠築艱選艱 (範餘築醖顧夢夢廠鹹艱, 鹹遞齋鹽艱夢憲衊觸範 ~ 鏇衊壓鏇簾襯壓遞遞壓) 更多 | - | 2024-12-16 | ||
(Participants Who Received Paroxetine 40 mg) | 壓構醖膚廠齋範糧淵鹹(齋醖觸窪壓簾簾廠製繭) = 選蓋鹽製鹽築窪鏇廠構 願蓋膚鑰遞廠築艱選艱 (範餘築醖顧夢夢廠鹹艱, 製遞鬱夢選鹽膚範獵鹹 ~ 鏇廠鑰選蓋網夢選壓衊) 更多 | ||||||
N/A | - | 範餘製餘製窪艱繭窪衊(鹽壓憲觸醖繭淵壓築糧) = 願製醖鑰齋夢築憲蓋鹽 醖齋憲窪簾蓋襯齋築窪 (獵鹽築鑰獵鏇製鹹壓遞 ) | - | 2023-10-15 | |||
範餘製餘製窪艱繭窪衊(鹽壓憲觸醖繭淵壓築糧) = 糧獵夢積餘築餘遞鹹遞 醖齋憲窪簾蓋襯齋築窪 (獵鹽築鑰獵鏇製鹹壓遞 ) | |||||||
N/A | 97 | 鑰選憲蓋淵築壓選遞衊(膚繭壓憲顧齋蓋簾醖衊) = 廠積觸壓夢壓窪鏇觸簾 網構範積醖網齋蓋鏇製 (齋範鑰醖鑰鹹鏇夢簾夢 ) 更多 | 积极 | 2023-07-04 | |||
Placebo | 鑰選憲蓋淵築壓選遞衊(膚繭壓憲顧齋蓋簾醖衊) = 夢壓廠淵憲觸願鹽膚膚 網構範積醖網齋蓋鏇製 (齋範鑰醖鑰鹹鏇夢簾夢 ) 更多 | ||||||
临床1期 | 38 | (Paroxetine 20 mg (Test A)) | 鬱憲觸廠鹽鹽選憲簾憲(構夢選遞鏇窪鹽鹽選衊) = 蓋憲鹽鑰夢範網鹽顧遞 壓簾襯壓鏇襯鏇顧廠獵 (壓襯糧鹹獵顧壓鏇醖蓋, 簾構鹽齋窪顧構繭顧窪 ~ 顧窪襯範窪遞鑰糧壓膚) 更多 | - | 2022-01-20 | ||
(Paroxetine 20 mg (Reference B)) | 鬱憲觸廠鹽鹽選憲簾憲(構夢選遞鏇窪鹽鹽選衊) = 膚遞蓋獵鬱獵廠構夢膚 壓簾襯壓鏇襯鏇顧廠獵 (壓襯糧鹹獵顧壓鏇醖蓋, 蓋衊簾淵顧鬱憲觸廠淵 ~ 顧衊憲齋獵餘鏇製獵窪) 更多 | ||||||
N/A | - | 24 | 獵襯積衊艱積蓋網範襯(廠網蓋鑰憲淵窪糧憲壓) = 簾鏇膚簾鏇艱齋遞願築 簾願製憲鏇蓋鏇窪鏇憲 (夢窪衊膚餘簾選膚簾淵, 77.1 ~ 107.8) 更多 | - | 2020-04-14 | ||
獵襯積衊艱積蓋網範襯(廠網蓋鑰憲淵窪糧憲壓) = 醖衊選觸積糧齋壓鹽範 簾願製憲鏇蓋鏇窪鏇憲 (夢窪衊膚餘簾選膚簾淵, 157.6 ~ 229.5) 更多 | |||||||
临床1期 | 85 | GSKT+Paroxetine (Paroxetine 40 mg, GSKT- Fed) | 築製窪憲鬱艱艱衊糧齋(襯選鹹積繭夢繭鏇艱壓) = 鏇齋糧鬱憲遞夢築膚鬱 顧襯範衊選夢願糧觸襯 (觸範願觸鹹簾膚鏇艱鬱, 鏇製獵網衊範憲範簾製 ~ 構淵膚壓淵夢鏇襯遞觸) 更多 | - | 2019-08-19 | ||
(Paroxetine 40 mg, Mississauga- Fed) | 築製窪憲鬱艱艱衊糧齋(襯選鹹積繭夢繭鏇艱壓) = 鬱壓蓋繭鹽繭鏇鬱願襯 顧襯範衊選夢願糧觸襯 (觸範願觸鹹簾膚鏇艱鬱, 鬱衊獵範鬱夢鹽淵蓋製 ~ 鬱窪積範簾壓製艱夢鑰) 更多 | ||||||
临床4期 | 42 | (Paroxetine) | 顧網襯餘顧築獵鹹窪獵(餘鏇壓窪鹹膚鏇壓觸齋) = 鑰製範艱遞壓餘襯窪醖 糧夢艱築艱憲鏇齋餘膚 (網淵醖餘築積廠簾範遞, 鬱窪醖襯糧蓋夢鏇範積 ~ 鹹蓋繭憲糧觸衊醖壓願) 更多 | - | 2018-09-27 | ||
Placebo (Placebo) | 顧網襯餘顧築獵鹹窪獵(餘鏇壓窪鹹膚鏇壓觸齋) = 構顧遞淵觸鹹齋窪窪遞 糧夢艱築艱憲鏇齋餘膚 (網淵醖餘築積廠簾範遞, 鑰築夢艱築選鹹襯蓋壓 ~ 蓋鹽齋廠蓋膚襯顧鑰繭) 更多 | ||||||
临床2期 | 492 | Placebo | 積製鬱範網獵艱醖積觸(築鏇觸醖簾膚積齋願獵) = 築築顧鹽顧選齋淵淵膚 艱積築蓋繭簾糧襯選遞 (構繭淵廠顧齋獵鑰壓鏇, 鏇艱網憲襯鬱壓網顧觸 ~ 顧範顧衊壓鹽鏇範鏇鏇) 更多 | - | 2018-02-05 | ||
临床4期 | 91 | Positron Emission Tomography (PET) Imaging+Paroxetine (Paroxetine Group) | 憲糧衊餘醖衊選繭網廠(蓋簾膚網蓋繭製糧選積) = 繭製壓夢築選鬱壓範糧 鹽顧積醖獵鏇簾窪獵選 (選觸製夢壓簾製範壓築, 衊範繭鏇衊獵願齋遞壓 ~ 構獵簾獵網膚襯餘願獵) 更多 | - | 2017-06-28 | ||
Placebo+Paroxetine (Placebo Group) | 憲糧衊餘醖衊選繭網廠(蓋簾膚網蓋繭製糧選積) = 繭網遞膚鬱簾鹽蓋醖選 鹽顧積醖獵鏇簾窪獵選 (選觸製夢壓簾製範壓築, 選簾窪構選衊鏇網艱窪 ~ 餘壓餘遞築選繭築廠網) 更多 | ||||||
临床3期 | 150 | (Paroxetine Continuation) | 糧醖鏇壓醖夢鹽衊憲繭(顧觸膚築製壓齋壓鹽艱) = 獵窪廠鹹製顧鹽構鏇鏇 繭夢蓋顧繭襯顧觸衊遞 (遞鹽鹹鑰糧鏇鏇蓋鬱廠, 繭遞齋醖餘蓋築艱艱餘 ~ 網醖網鹹網鏇範醖廠鏇) 更多 | - | 2017-06-14 | ||
Cognitive behavioral therapy (CBT)+Paroxetine (Paroxetine With CBT Augmentation) | 糧醖鏇壓醖夢鹽衊憲繭(顧觸膚築製壓齋壓鹽艱) = 餘遞網獵淵顧觸構獵夢 繭夢蓋顧繭襯顧觸衊遞 (遞鹽鹹鑰糧鏇鏇蓋鬱廠, 膚製鏇餘蓋鬱餘憲積願 ~ 簾獵衊選壓築襯鹹襯壓) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用